文献速递中医内科中药与中成药合理使用

银翘散合麻杏石甘汤治疗轻中型新冠主要症状的随机双盲安慰剂对照试验方案

Assessing the efficacy and safety of Yinqiao powder-maxing Ganshi decoction in the treatment of the major symptoms of mild and moderate COVID-19 by telemedicine-study protocol for a randomized, double-blind, placebo-controlled trial.
PubMed 文献 · Front Pharmacol · 2024-01-08

本研究为随机双盲安慰剂对照试验方案,通过远程医疗评估银翘散合麻杏石甘汤随症加减治疗轻中型COVID-19主要症状的疗效与安全性。受试者按年龄和疫苗接种剂数分层后随机分入治疗组或安慰剂组,疗程最长14天,主要结局为体温恢复正常时间。

要点

  • 银翘散合麻杏石甘汤随症加减用于轻中型COVID-19,疗程最长14天。
  • 按年龄(18-49/50-65岁)和疫苗接种剂数(≥3/≤2剂)分层随机。
  • 主要结局为体温恢复正常时间,第7、14、35天视频随访评估。

核心结论

  • 该试验旨在为银翘散合麻杏石甘汤治疗COVID-19提供科学证据,并提升香港及国际社会对中药治疗COVID-19的认识。

研究设计与样本

  • 研究为随机、双盲、安慰剂对照试验,采用远程医疗方式实施。
  • 合格受试者按年龄(A:18-49岁,B:50-65岁)和疫苗接种剂数(a:≥3剂,b:≤2剂)分层后随机分为治疗组或安慰剂组,疗程最长14天。

关键数值与推荐

  • 治疗组接受银翘散合麻杏石甘汤颗粒并根据症状进行相应加减,安慰剂组接受等量安慰剂颗粒。
  • 受试者入组时根据症状和病机给予不同加减。
  • 受试者记录口腔温度、血氧仪读数、快速抗原检测结果和症状评分直至停药。
  • 受试者需在第7、14和35天通过视频会议进行随访评估。
  • 主要结局为体温恢复正常的时间。

临床怎么用

  • 该方案提示在远程医疗条件下,可对轻中型COVID-19患者使用银翘散合麻杏石甘汤随症加减进行干预并系统监测体温、血氧和抗原结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The Coronavirus disease 2019 (COVID-19) is the largest global epidemic in recent time. Chinese medicine has been recognized by the World Health Organization as an effective treatment for COVID-19, but there is still a lack of high-quality randomized, double-blind trials using placebo as the control to support its application, which may hinder its further promotion locally and internationally. Objectives: This study will evaluate the efficacy and safety of Yinqiao Powder-Maxing Ganshi Decoction with variation in relieving major symptoms of mild and moderate COVID-19 by telemedicine. Methods and design: This clinical study is a randomized, double-blind, placebo-controlled trial that applies telemedicine to evaluate the efficacy and safety of Yinqiao Powder-Maxing Ganshi Decoction in the treatment of mild and moderate COVID-19. Eligible subjects will be randomly divided into either treatment or placebo groups for up to 14 days after stratification according to age (A:18-49, B:50-65) and the number of vaccinations (a: ≥3 doses, b: ≤2 doses). The treatment group will receive Yinqiao Powder-Maxing Ganshi Decoction granules along with certain variation based on their symptoms, and the placebo group will receive the same amount of placebo granules. Subjects will be prescribed different additions based on their symptoms and pathogenesis at the inclusion. The oral temperature, oximeter, result of rapid antigen test and symptom score will be recorded by subjects until they have stopped the medication. Subjects are required to have follow-up assessment by video-conference on days 7, 14 and 35. The time for the body temperature returning to normal will be used as the primary outcome. Discussion: This trial will provide scientific evidence on the use of Yinqiao Powder-Maxing Ganshi Decoction for the treatment of COVID-19, and the results would help raise the awareness in Hong Kong and the international community on the use of Chinese herbal medicine for treating COVID-19. Clinical Trial Registration: clinicaltrials.gov, identifier NCT05787327.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Sum CH, Li TW, Zhang H, et al. Assessing the efficacy and safety of Yinqiao powder-maxing Ganshi decoction in the treatment of the major symptoms of mild and moderate COVID-19 by telemedicine-study protocol for a randomized, double-blind, placebo-controlled trial. Front Pharmacol. 2024. PMID: 38259270. doi:10.3389/fphar.2023.1261338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。